MIMS Doctor spoke to Dr Kho Sze Shyang, of Sarawak General Hospital, who won not one, but two awards at the recent International Association for the Study of Lung Cancer (IASLC) 18th World Conference on Lung Cancer (WCLC), held in Yokohama, Japan. The two papers that Kho submitted won him the IASLC International Mentorship Program and the WCLC 2017 Developing Nation Travel Awards.
Integrating robust smoking cessation programs with organized low-dose CT (LDCT) lung cancer screening may decrease mortality rates while being relatively cost-effective, according to a modelling study.
Customizing chemotherapy (CT) treatment based on BRCA1 expression levels of post-operative patients with stage II/III non-small-cell lung cancer (NSCLC) does not affect overall survival (OS) versus standard treatment, say researchers.
On-the-ground education focused on changing knowledge, beliefs and attitudes towards cancer may be key to reducing disproportionately high mortality rates among underserved minority communities, say researchers.
The introduction of early specialist palliative care for patients recently diagnosed with malignant pleural mesothelioma (MPM) has no impact on the quality of life (QOL) scores, reveals a research presented by Professor Fraser Brims, of Curtin University Australia, at the recent International Association for the Study of Lung Cancer (IASLC) 18th World Conference on Lung Cancer (WCLC), held recently in Yokohama, Japan.
Transitioning from bortezomib- to ixazomib-based induction is feasible, tolerable and effective in the treatment of community patients with newly diagnosed multiple myeloma (NDMM), according to a study presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).
Research on the role of circulating tumour DNA (ctDNA) in metastatic castration-resistant prostate cancer (mCRPC) gains momentum, as a new study finds ctDNA assessment promising in the monitoring and prognosis of mCRPC and in identifying new therapeutic targets for the disease.
At the recent National Haematology Expert Meeting 2019, a panel of experts was convened to discuss the role of targeted therapy in the management of haematological malignancies. Highlights of their lectures are summarised below.
Neoadjuvant chemotherapy with S-1 and oxaliplatin (SOX) may be a suitable treatment measure for patients with advanced gastric or esophagogastric junction adenocarcinoma, according to the RESONANCE* trial presented at ASCO GI 2020.